262 related articles for article (PubMed ID: 27002986)
21. Targeted delivery of 5-fluorouracil to HT-29 cells using high efficient folic acid-conjugated nanoparticles.
Wang Y; Li P; Chen L; Gao W; Zeng F; Kong LX
Drug Deliv; 2015 Feb; 22(2):191-8. PubMed ID: 24437926
[TBL] [Abstract][Full Text] [Related]
22. Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer.
Saxena V; Naguib Y; Hussain MD
Colloids Surf B Biointerfaces; 2012 Jun; 94():274-80. PubMed ID: 22377218
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel-loaded nanoparticles based on star-shaped mannitol-core PLGA-TPGS diblock copolymer for breast cancer therapy.
Tao W; Zeng X; Liu T; Wang Z; Xiong Q; Ouyang C; Huang L; Mei L
Acta Biomater; 2013 Nov; 9(11):8910-20. PubMed ID: 23816645
[TBL] [Abstract][Full Text] [Related]
24. Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity.
Singh R; Kesharwani P; Mehra NK; Singh S; Banerjee S; Jain NK
Drug Dev Ind Pharm; 2015; 41(11):1888-901. PubMed ID: 25738812
[TBL] [Abstract][Full Text] [Related]
25. Targeted and controlled drug delivery system loading artersunate for effective chemotherapy on CD44 overexpressing cancer cells.
Tran TH; Nguyen TD; Van Nguyen H; Nguyen HT; Kim JO; Yong CS; Nguyen CN
Arch Pharm Res; 2016 May; 39(5):687-94. PubMed ID: 27015824
[TBL] [Abstract][Full Text] [Related]
26. Enhancing the in vitro anti-cancer efficacy of artesunate by loading into poly-D,L-lactide-co-glycolide (PLGA) nanoparticles.
Nguyen HT; Tran TH; Kim JO; Yong CS; Nguyen CN
Arch Pharm Res; 2015; 38(5):716-24. PubMed ID: 24968925
[TBL] [Abstract][Full Text] [Related]
27. Enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HPβCD in polymeric nanoparticles.
Kadari A; Gudem S; Kulhari H; Bhandi MM; Borkar RM; Kolapalli VR; Sistla R
Drug Deliv; 2017 Nov; 24(1):224-232. PubMed ID: 28156161
[TBL] [Abstract][Full Text] [Related]
28. Preparation and characterization of teniposide PLGA nanoparticles and their uptake in human glioblastoma U87MG cells.
Mo L; Hou L; Guo D; Xiao X; Mao P; Yang X
Int J Pharm; 2012 Oct; 436(1-2):815-24. PubMed ID: 22846410
[TBL] [Abstract][Full Text] [Related]
29. Comparison, synthesis and evaluation of anticancer drug-loaded polymeric nanoparticles on breast cancer cell lines.
Eatemadi A; Darabi M; Afraidooni L; Zarghami N; Daraee H; Eskandari L; Mellatyar H; Akbarzadeh A
Artif Cells Nanomed Biotechnol; 2016 May; 44(3):1008-17. PubMed ID: 25707442
[TBL] [Abstract][Full Text] [Related]
30. Nano-precipitated curcumin loaded particles: effect of carrier size and drug complexation with (2-hydroxypropyl)-β-cyclodextrin on their biological performances.
Serri C; Argirò M; Piras L; Mita DG; Saija A; Mita L; Forte M; Giarra S; Biondi M; Crispi S; Mayol L
Int J Pharm; 2017 Mar; 520(1-2):21-28. PubMed ID: 28130197
[TBL] [Abstract][Full Text] [Related]
31. PLGA-based microparticles loaded with bacterial-synthesized prodigiosin for anticancer drug release: Effects of particle size on drug release kinetics and cell viability.
Obayemi JD; Danyuo Y; Dozie-Nwachukwu S; Odusanya OS; Anuku N; Malatesta K; Yu W; Uhrich KE; Soboyejo WO
Mater Sci Eng C Mater Biol Appl; 2016 Sep; 66():51-65. PubMed ID: 27207038
[TBL] [Abstract][Full Text] [Related]
32. Polymeric emulsion and crosslink-mediated synthesis of super-stable nanoparticles as sustained-release anti-tuberculosis drug carriers.
Choonara YE; Pillay V; Ndesendo VM; du Toit LC; Kumar P; Khan RA; Murphy CS; Jarvis DL
Colloids Surf B Biointerfaces; 2011 Oct; 87(2):243-54. PubMed ID: 21664111
[TBL] [Abstract][Full Text] [Related]
33. Preparation of wormlike polymeric nanoparticles coated with silica for delivery of methotrexate and evaluation of anticancer activity against MCF7 cells.
Gharebaghi F; Dalali N; Ahmadi E; Danafar H
J Biomater Appl; 2017 Apr; 31(9):1305-1316. PubMed ID: 28447548
[TBL] [Abstract][Full Text] [Related]
34. Antiproliferative effect of ASC-J9 delivered by PLGA nanoparticles against estrogen-dependent breast cancer cells.
Verderio P; Pandolfi L; Mazzucchelli S; Marinozzi MR; Vanna R; Gramatica F; Corsi F; Colombo M; Morasso C; Prosperi D
Mol Pharm; 2014 Aug; 11(8):2864-75. PubMed ID: 24945469
[TBL] [Abstract][Full Text] [Related]
35. A modified double-emulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhanced in vitro anti-tumor activity.
Liu J; Qiu Z; Wang S; Zhou L; Zhang S
Biomed Mater; 2010 Dec; 5(6):065002. PubMed ID: 20924138
[TBL] [Abstract][Full Text] [Related]
36. Co-association of methotrexate and SPIONs into anti-CD64 antibody-conjugated PLGA nanoparticles for theranostic application.
Moura CC; Segundo MA; Neves Jd; Reis S; Sarmento B
Int J Nanomedicine; 2014; 9():4911-22. PubMed ID: 25364249
[TBL] [Abstract][Full Text] [Related]
37. PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3.
Bol GM; Khan R; Heerma van Voss MR; Tantravedi S; Korz D; Kato Y; Raman V
Cancer Chemother Pharmacol; 2015 Oct; 76(4):821-7. PubMed ID: 26330329
[TBL] [Abstract][Full Text] [Related]
38. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery.
Parveen S; Sahoo SK
Eur J Pharmacol; 2011 Nov; 670(2-3):372-83. PubMed ID: 21951969
[TBL] [Abstract][Full Text] [Related]
39. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
[TBL] [Abstract][Full Text] [Related]
40. Development of a new delivery system consisting in 'drug-in cyclodextrin-in PLGA nanoparticles'.
Mura P; Maestrelli F; Cecchi M; Bragagni M; Almeida A
J Microencapsul; 2010; 27(6):479-86. PubMed ID: 20113170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
